Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

1. Management of Type 2 Diabetes Mellitus

complications. Key points Prevention. In individuals at risk for type 2 diabetes (see Table 1), type 2 diabetes can be delayed or prevented through diet, exercise, and pharmacologic interventions [IA]. Screening. Although little evidence is available on screening for diabetes, screening should be considered every 3 years beginning at age 45 or annually at any age if BMI = 25 kg/m 2 [evidence: IID], history of hypertension [IIB], gestational diabetes [IC], or other risk factors. Diagnosis. An A1c of 6.5 (...) = generally should not be performed. Level of evidence supporting a diagnostic method or an intervention: A=randomized controlled trials; B=controlled trials, no randomization; C=observational trials; D=opinion of expert panel. 2 UMHS Management of Type 2 Diabetes Mellitus June, 2017 Table 1. Diagnosis of Diabetes: Diagnostic Tests and Glucose Values Diagnostic Test Normal Pre-diabetes Diabetes Hemoglobin A1c (A1c) a 30 mg/gm, check UA to rule out asymptomatic UTI. • Repeat spot urine ratio twice within 6

2020 University of Michigan Health System

2. Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY

Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY | American Association of Clinical Endocrinologists search Search Resources BACK Offering Guidance Through the Latest Science on Bone-Related Disorders Treat your diabetes patients with expert precision. Offering Guidance Through the Latest Science on Lipid Conditions Education Menu FEATURED EMBR AACE 2020 EMBR AACE , the AACE 29 th Annual (...) to enhancing our members’ knowledge, education, and practice management skills so they can focus on providing the highest quality of patient care. We also advocate for the profession to create understanding of the value of our community to patients, organizations and the public. search Breadcrumb Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY Footer Navigation Partner With Us Join us to develop an open dialogue between industry and foster AACE in the furtherance of patient

2020 American Association of Clinical Endocrinologists

3. Sotagliflozin with insulin for treating type 1 diabetes

Sotagliflozin with insulin for treating type 1 diabetes Sotagliflozin with insulin for treating type 1 diabetes T echnology appraisal guidance Published: 12 February 2020 www.nice.org.uk/guidance/ta622 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sotagliflozin with insulin for treating type 1 diabetes (TA622) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about sotagliflozin 6 3 Committee discussion 7 Clinical management 7 Experience of people

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes (Abstract)

Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes Patients with diabetes mellitus (DM) have elevated levels of high-sensitivity cardiac troponin (hs-cTn). We investigated the diagnostic performance of the European Society of Cardiology (ESC) algorithms to rule out or rule in acute myocardial infarction (AMI) without ST-elevation in patients with DM.We prospectively enrolled 3,681 patients (...) with suspected AMI and stratified those by the presence of DM. The ESC 0/1-h and 0/3-h algorithms were used to calculate negative and positive predictive values (NPV, PPV). In addition, alternative cutoffs were calculated and externally validated in 2,895 patients.In total, 563 patients (15.3%) had DM, and 137 (24.3%) of these had AMI. When the ESC 0/1-h algorithm was used, the NPV was comparable in patients with and without DM (absolute difference [AD] -1.50 [95% CI -5.95, 2.96]). In contrast, the ESC 0/3-h

2020 EvidenceUpdates

5. GLP-1 receptor agonists and stroke outcomes among patients with type 2 diabetes: a systematic review and meta-analysis

GLP-1 receptor agonists and stroke outcomes among patients with type 2 diabetes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) : Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2

2020 PROSPERO

6. Genetic epidemiology in susceptibility to type 2 diabetes mellitus in the Brazilian population: systematic review

Genetic epidemiology in susceptibility to type 2 diabetes mellitus in the Brazilian population: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal

2020 PROSPERO

7. Screening strategies for type 2 diabetes mellitus: a systematic review protocol

Screening strategies for type 2 diabetes mellitus: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email (...) will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary

2020 PROSPERO

8. Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study

Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA 1c in Andalusia (Spain): PLATEDIAN Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome (...) collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions , 43 (2), 337-342 Feb 2020 Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin

2020 EvidenceUpdates

9. Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial Full Text available with Trip Pro

, , , , , , Affiliations Expand Affiliations 1 Department of Hematology, Endocrinology and Metabolism, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 2 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan. 3 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany. 4 Jikei University School of Medicine, Tokyo, Japan. PMID: 31692244 DOI: Item in Clipboard Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind (...) -text links Cite Abstract Aim: To assess the efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes (T2D). Materials and methods: This multicentre, double-blind, parallel-group study randomized Japanese patients with T2D insufficiently controlled with insulin (1:1:1) to empagliflozin 10 mg (n=89), empagliflozin 25 mg (n=90) or placebo (n=90) for 52 weeks. The primary endpoint was change from baseline in glycated haemoglobin (HbA1c) at 16 weeks. Results

2020 EvidenceUpdates

10. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria

your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Diabet Med Actions , 37 (1), 44-52 Jan 2020 Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People With Type 2 Diabetes and Proteinuria (...) , , , , Affiliations Expand Affiliations 1 University of Connecticut School of Pharmacy, Storrs, CT, USA. 2 College of Pharmacy at the Medical University of South Carolina, Charleston, SC, USA. 3 Janssen Scientific Affairs, LLC, Titusville, NJ, USA. PMID: 31407377 DOI: Item in Clipboard Review Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People With Type 2 Diabetes and Proteinuria C I Coleman et al. Diabet Med . Jan 2020 Show details Diabet

2020 EvidenceUpdates

11. Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial

of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial Simon J Griffin et al. Lancet Diabetes Endocrinol . Dec 2019 Show details Lancet Diabetes Endocrinol Actions , 7 (12), 925-937 Authors , , , , , , , , , , , , Affiliations 1 MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Primary Care Unit, Institute of Public Health, School of Clinical (...) . Diabetologia 56 (11), 2367-2377. 2013. PMID 23959571. There were no differences in health status, well-being, quality of life and treatment satisfaction between screen-detected type 2 diabetes mellitus patients receiving int … RK Simmons et al. Health Technol Assess 20 (64), 1-86. Aug 2016. PMID 27583404. - Randomized Controlled Trial Compared with RC, IT was associated with modest increases in prescribed treatment, reduced levels of risk factors and non-significant reductions in cardiovascular events, … X

2020 EvidenceUpdates

12. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes

Diabetes , , , , , Affiliations Expand Affiliations 1 Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts, United States. 2 Prometrika, LLC, Cambridge, Massachusetts. PMID: 31749238 DOI: Item in Clipboard A 12-week, Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Phase 2 Study Evaluating Bexagliflozin as Monotherapy for Adults With Type 2 Diabetes Yuan-Di Halvorsen et al. Diabetes Obes Metab . 2019 (...) Show details Diabetes Obes Metab Actions Authors , , , , , Affiliations 1 Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts, United States. 2 Prometrika, LLC, Cambridge, Massachusetts. PMID: 31749238 DOI: Item in Clipboard Full-text links Cite Abstract Aim: To compare the safety and efficacy of bexagliflozin administered as monotherapy at three dosage strengths over a 12-week period to patients with type 2 diabetes

2020 EvidenceUpdates

13. Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Prescrire IN ENGLISH - Spotlight ''Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications'', 1 January 2020 {1} {1} {1} | | > > > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...) versus placebo included more than 17 000 patients with type 2 diabetes, half of whom were followed for at least 4 years. In this trial, dapagliflozin did not reduce the rate of cardiovascular complications of diabetes, or death. Full text available for free download. ©Prescrire 1 January 2020 Share Share Download the full review See also: Dapagliflozin. A hypoglycaemic drug causing disproportionate harm, especially to kidneys Prescrire Int 2014; 23 (147): 61-64. | | | Prescrire Your change of address

2020 Prescrire

14. Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value

Examination Survey NMA Network meta-analysis OM1 Outcomes Model 1 OM2 Outcomes Model 2 LCD Local coverage decision LY Life year PICOTS Population, Intervention, Comparator, and Study Design PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRO Patient-reported outcome ©Institute for Clinical and Economic Review, 2019 Page ix Final Evidence Report – Oral Semaglutide for Type 2 Diabetes Return to Table of Contents QALY Quality-adjusted life year RCT Randomized control trial SAE (...) Summary Background In the United States (US), approximately 30 million individuals have diabetes mellitus, of whom 95% have Type 2 diabetes mellitus (T2DM). 1 Patients with diabetes have elevations in blood glucose (hyperglycemia) and are at increased risk for damage to blood vessels both large (macrovascular disease) and small (microvascular disease). Many of the complications of diabetes are the result of vascular disease, including microvascular damage to the eyes and kidneys, and macrovascular

2020 California Technology Assessment Forum

15. Zingiber officinale (Ginger) for type 2 diabetes mellitus. A systematic review and meta-analysis

Zingiber officinale (Ginger) for type 2 diabetes mellitus. A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) : Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3

2020 PROSPERO

16. Systematic review of non-pharmacological interventions targeting type 2 diabetes mellitus and mental health co-morbidity in adults with severe mental illness

Systematic review of non-pharmacological interventions targeting type 2 diabetes mellitus and mental health co-morbidity in adults with severe mental illness Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) : Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review

2020 PROSPERO

17. The effectiveness of mobile phone messaging-based interventions to promote physical activity in type 2 diabetes: a systematic review

The effectiveness of mobile phone messaging-based interventions to promote physical activity in type 2 diabetes: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2

2020 PROSPERO

18. Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: a systematic review and meta-analysis

Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2

2020 PROSPERO

19. Comparing effects of continuous glucose monitoring systems (CGMs) and self-monitoring of blood glucose (SMBG) among adults with type 2 diabetes mellitus: a systematic review

Comparing effects of continuous glucose monitoring systems (CGMs) and self-monitoring of blood glucose (SMBG) among adults with type 2 diabetes mellitus: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) : Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper

2020 PROSPERO

20. Comparative effect of glucose lowering drugs use on exercise capacity and muscle mass in patients with type 2 diabetes: a network meta-analysis

Comparative effect of glucose lowering drugs use on exercise capacity and muscle mass in patients with type 2 diabetes: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) : Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review

2020 PROSPERO